Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark

Sidsel Arnspang Pedersen; A Pottegård; S Friis; Ole Clemmensen; Klaus Ejner Andersen; J Hallas; D Gaist; Klaus Ejner Andersen

doi:10.1038/bjc.2014.527

Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark

Sidsel Arnspang Pedersen, A Pottegård, S Friis, Ole Clemmensen, Klaus Ejner Andersen, J Hallas, D Gaist, Klaus Ejner Andersen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstrakt

Background: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC). Methods: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use. Results: We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC. Conclusions: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.

Originalsprog	Engelsk
Tidsskrift	British Journal of Cancer
Vol/bind	112
Udgave nummer	1
Sider (fra-til)	153-156
ISSN	0007-0920
DOI	https://doi.org/10.1038/bjc.2014.527
Status	Udgivet - 6. jan. 2015

Dokumenter og links

10.1038/bjc.2014.527

Fingeraftryk Dyk ned i forskningsemnerne om 'Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark'. Sammen danner de et unikt fingeraftryk.

Citationsformater

@article{28f1f7365ebe45b2aa4d9b54b792cd55,

title = "Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark",

abstract = "Background: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC). Methods: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use. Results: We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC. Conclusions: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.",

keywords = "Denmark, epidemiology, nonmelanoma, risk, skin cancer, statins, Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage, Humans, Middle Aged, Male, Risk, Case-Control Studies, Skin Neoplasms/epidemiology, Denmark/epidemiology, Aged, 80 and over, Adult, Female, Aged",

author = "Pedersen, {Sidsel Arnspang} and A Potteg{\aa}rd and S Friis and Ole Clemmensen and Andersen, {Klaus Ejner} and J Hallas and D Gaist and Andersen, {Klaus Ejner}",

year = "2015",

month = jan,

day = "6",

doi = "10.1038/bjc.2014.527",

language = "English",

volume = "112",

pages = "153--156",

journal = "B J C",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

Statin use and risk of nonmelanoma skin cancer : a nationwide study in Denmark. / Pedersen, Sidsel Arnspang ; Pottegård, A; Friis, S; Clemmensen, Ole; Andersen, Klaus Ejner; Hallas, J ; Gaist, D; Andersen, Klaus Ejner.

I: British Journal of Cancer, Bind 112, Nr. 1, 06.01.2015, s. 153-156.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Statin use and risk of nonmelanoma skin cancer

T2 - a nationwide study in Denmark

AU - Pedersen, Sidsel Arnspang

AU - Pottegård, A

AU - Friis, S

AU - Clemmensen, Ole

AU - Andersen, Klaus Ejner

AU - Hallas, J

AU - Gaist, D

AU - Andersen, Klaus Ejner

PY - 2015/1/6

Y1 - 2015/1/6

N2 - Background: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC). Methods: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use. Results: We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC. Conclusions: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.

AB - Background: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC). Methods: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use. Results: We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC. Conclusions: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.

KW - Denmark

KW - epidemiology

KW - nonmelanoma

KW - risk

KW - skin cancer

KW - statins

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage

KW - Humans

KW - Middle Aged

KW - Male

KW - Risk

KW - Case-Control Studies

KW - Skin Neoplasms/epidemiology

KW - Denmark/epidemiology

KW - Aged, 80 and over

KW - Adult

KW - Female

KW - Aged

U2 - 10.1038/bjc.2014.527

DO - 10.1038/bjc.2014.527

M3 - Journal article

C2 - 25290087

VL - 112

SP - 153

EP - 156

JO - B J C

JF - B J C

SN - 0007-0920

IS - 1

ER -